Redeye publishes research update on Calmark
Analyst firm Redeye has today published a research update: "Calmark: Untapped Potential".
“Redeye reviews its assessment of Calmark to acknowledge the rapid establishment of the company’s commercial infrastructure on several markets and the prospects for its COVID19-LDH test. We hike our fair value range owing to this more optimistic take on the case.“
Read the full update: https://www.redeye.se/research/824617/calmark-untapped-potential
Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.
För mer information om Calmark Sweden AB, vänligen kontakta:
Anna Söderlund, VD
Telefon: +46 70 214 98 93
Calmark Sweden AB is a medical technology company that develops and markets a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, was launched to the market in 2020. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. In addition to products for newborns, Calmark sells a POC test for assessment of COVID-19 disease severity. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.